Researchers develop new compound to fight cytomegalovirus

January 10, 2017, Pennsylvania State University

A Retro94-based compound may prevent a common and sometimes fatal virus—human cytomegalovirus (CMV)—from reproducing and help to protect immunocompromised patients, such as those with HIV, on chemotherapy, with transplants, and infants from the effects of the disease, according to Penn State College of Medicine researchers.

New therapies for CMV are needed, said Nicholas J. Buchkovich, assistant professor of microbiology and immunology and lead researcher. The current treatments for CMV in immunosuppressed patients can have toxic side effects, and emerging mutations in the are developing resistance to existing therapies.

The Retro94-based compound effectively stops the virus from making copies of itself. This means that immunocompromised patients with active CMV infection could be treated with anti-viral medication or even protected from the virus reactivating in the body before it occurs. The results were recently published in the Journal of Virology.

While about 50 percent of Americans have been infected with CMV, in developing countries this number can approach 100 percent of the adult population. Although the virus is generally harmless, it can cause serious health problems in people with suppressed immune systems.

CMV also is the most common infection present from birth, and infants born with CMV can suffer from hearing loss, vision problems, microcephaly—a condition that involves an abnormal smallness of the head—and intellectual deficits. CMV is the leading nongenetic cause of deafness and results in the deaths of hundreds of children annually. CMV also has a major impact on morbidity and mortality of transplant patients and is often associated with transplant rejection.

After CMV infects a human cell, it creates a compartment where proteins are assembled into infectious viral particles. These virus particles then escape the cell to invade new ones, spreading infection. A key goal for the researchers is to understand how this assembly compartment forms. The level of Syntaxin 5 protein is increased in CMV-infected cells. The virus appears to recruit this protein from the host cell to generate the assembly compartment.

When the researchers used a genetic technique called miRNA knockdown to decrease this protein in CMV-infected cells, the compartments formed irregular shapes and produced fewer new .

Previous work suggested that the Retro94 molecule interferes with Syntaxin 5. Knowing this, the researchers then developed, in collaboration with Dhimant Desai and Shantu Amin in the department of pharmacology, a Retro94-based compound and tested its effect in CMV-infected cells in the laboratory.

"We knew of a compound that modulates Syntaxin 5," Buchkovich explained. "We tested to see if that would inhibit the formation of the assembly compartment and, in turn, inhibit the actual production of the virus. That is, in fact, what we found."

The CMV assembly compartments also formed irregularly in the presence of the compound. Importantly, the compound did not harm the host cells.

The findings suggest that Retro94 should be studied further as a potential effective and safe therapy against human CMV that interferes with the viral assembly compartment.

Buchkovich is now planning to test the compound in an animal model.

Explore further: Researchers find how Ebola disables the immune system

Related Stories

Researchers find how Ebola disables the immune system

December 6, 2016
A new study at The University of Texas Medical Branch in Galveston sheds light on how Ebola so effectively disables the human immune system.

Discovery could turn the tables on influenza virus

September 12, 2014
(Medical Xpress)—University of Otago virologist Dr Matloob Husain has identified a potential new weapon in the battle against the flu.

Study identifies how Zika virus infects the placenta

August 18, 2016
In a new study, Yale researchers demonstrate Zika virus infection of cells derived from human placentas. The research provides insight into how Zika virus may be transmitted from expectant mother to fetus, resulting in infection ...

Virus spread can be blocked by attacking Ebola's Achilles' heel

August 24, 2016
Scientists have found Ebola's Achilles' heel: a new kind of chemical compound can block the protein Ebola uses to break out of cells and infect new cells. The compounds, revealed in a new paper in Bioorganic & Medicinal Chemistry ...

Recommended for you

A new theory on reducing cardiovascular disease risk in binge drinkers

January 23, 2018
A new study shows that binge drinkers have increased levels of a biomarker molecule—microRNA-21—that may contribute to poor vascular function.

Flu infection study increases understanding of natural immunity

January 23, 2018
People with higher levels of antibodies against the stem portion of the influenza virus hemagglutinin (HA) protein have less viral shedding when they get the flu, but do not have fewer or less severe signs of illness, according ...

New long-acting approach for malaria therapy developed

January 22, 2018
A new study, published in Nature Communications, conducted by the University of Liverpool and the Johns Hopkins University School of Medicine highlights a new 'long acting' medicine for the prevention of malaria.

Virus shown to be likely cause of mystery polio-like illness

January 22, 2018
A major review by UNSW researchers has identified strong evidence that a virus called Enterovirus D68 is the cause of a mystery polio-like illness that has paralysed children in the US, Canada and Europe.

Creation of synthetic horsepox virus could lead to more effective smallpox vaccine

January 19, 2018
UAlberta researchers created a new synthetic virus that could lead to the development of a more effective vaccine against smallpox. The discovery demonstrates how techniques based on the use of synthetic DNA can be used to ...

Study ends debate over role of steroids in treating septic shock

January 19, 2018
The results from the largest ever study of septic shock could improve treatment for critically ill patients and save health systems worldwide hundreds of millions of dollars each year.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.